Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02053363 · ClinicalTrials.gov registry record · Phase 2
Tranexamic Acid Dosing in Adult Spinal Deformity Surgery
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT02053363 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 64 participants.
The verdict
NCT02053363, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate two dosing protocols for tranexamic acid (TXA), an anti-fibrinolytic used to decrease blood loss in adult patients undergoing complex, reconstructive spinal fusion surgeries.
Interventions
- DRUG Tranexamic Acid (Cyklokapron)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2014-03 |
| Est. Completion | 2020-06-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02053363
The ClinicalTrials.gov registry entry for NCT02053363 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tranexamic Acid (Cyklokapron) is the first listed.
NCT02053363 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02053363 about?
NCT02053363 is a clinical study titled "Tranexamic Acid Dosing in Adult Spinal Deformity Surgery". The purpose of this study is to evaluate two dosing protocols for tranexamic acid (TXA), an anti-fibrinolytic used to decrease blood loss in adult patients undergoing complex, reconstructive spinal fusion surgeries.
What is the current status of trial NCT02053363?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2014-03. Estimated completion is 2020-06-26.
What interventions are being tested in trial NCT02053363?
The interventions under investigation include: Tranexamic Acid (Cyklokapron) (DRUG).
Who is sponsoring clinical trial NCT02053363?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.